Theodora Katopodi
Overview
Explore the profile of Theodora Katopodi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
184
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Karpa V, Kalinderi K, Gavriilaki E, Antari V, Hatzipantelis E, Katopodi T, et al.
Curr Issues Mol Biol
. 2024 Oct;
46(10):11537-11547.
PMID: 39451565
Methotrexate (MTX) is an anti-folate chemotherapeutic agent that is considered to be a gold standard in Acute Lymphoblastic Leukemia (ALL) therapy. Nevertheless, toxicities induced mainly due to high doses of...
2.
Katopodi T, Petanidis S, Floros G, Porpodis K, Kosmidis C
Cells
. 2024 Jun;
13(11.
PMID: 38891040
The future of drug delivery offers immense potential for the creation of nanoplatforms based on nanogels. Nanogels present a significant possibility for pharmaceutical advancements because of their excellent stability and...
3.
Katopodi T, Petanidis S, Grigoriadou E, Anestakis D, Charalampidis C, Chatziprodromidou I, et al.
Pharmaceutics
. 2024 Apr;
16(4).
PMID: 38675116
Extensive research into mRNA vaccines for cancer therapy in preclinical and clinical trials has prepared the ground for the quick development of immune-specific mRNA vaccines during the COVID-19 pandemic. Therapeutic...
4.
Katopodi T, Petanidis S, Anestakis D, Charalampidis C, Chatziprodromidou I, Floros G, et al.
Front Immunol
. 2024 Jan;
14:1325360.
PMID: 38292487
A significant factor in the antitumor immune response is the increased metabolic reprogramming of immunological and malignant cells. Increasing data points to the fact that cancer metabolism affects not just...
5.
Katopodi T, Petanidis S, Anestakis D, Charalampidis C, Chatziprodromidou I, Floros G, et al.
Pharmaceutics
. 2023 Oct;
15(10).
PMID: 37896218
Following its therapeutic effect in hematological metastasis, chimeric antigen receptor (CAR) T cell therapy has gained a great deal of attention during the last years. However, the effectiveness of this...
6.
Demirtzoglou G, Chrysoglou S, Katopodi T, Dimitroulas T, Iakovidou-Kritsi Z, Garyfallos A, et al.
Cureus
. 2023 May;
15(4):e37683.
PMID: 37206523
Objectives: This study will investigate olanzapine's cytogenetic behavior in cultured human T lymphocytes in patients with systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Methods: Three olanzapine solutions were added...
7.
Katopodi T, Petanidis S, Tsavlis D, Anestakis D, Charalampidis C, Chatziprodromidou I, et al.
Front Oncol
. 2022 Nov;
12:1042125.
PMID: 36338748
The appearance of chemoresistance in cancer is a major issue. The main barriers to conventional tumor chemotherapy are undesirable toxic effects and multidrug resistance. Cancer nanotherapeutics were developed to get...
8.
Katopodi T, Petanidis S, Charalampidis C, Chatziprodromidou I, Eskitzis P, Tsavlis D, et al.
Cells
. 2022 Oct;
11(20).
PMID: 36291050
The tumor microenvironment plays a key role in progression of tumorigenesis, tumor progression, and metastasis. Accumulating data reveal that dendritic cells (DCs) appear to play a key role in the...
9.
Tilaveridis I, Katopodi T, Karakostas P, Venetis G, Dimitrakopoulos I, Tilaveridis S, et al.
Dent J (Basel)
. 2022 Oct;
10(10).
PMID: 36285992
The purpose of this article is to present four new cases of peripheral osteoma of the mandibular condyle and the literature review. A retrospective study of files from our Department...
10.
Domvri K, Petanidis S, Zarogoulidis P, Anestakis D, Charalampidis C, Tsavlis D, et al.
Int J Nanomedicine
. 2022 Sep;
17:4449-4468.
PMID: 36172007
Introduction: Tumor immunotherapy is a key therapeutic paradigm for the treatment of several malignancies. However, in metastatic lung cancer, classical immunotherapy regimes are ineffective due to regulatory T cell (Treg)-related...